Cancer
(108-25) A Phase 1 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors.
Contact usWhat is the purpose of this study?
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Eligibility
- Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.
- Have one or more measurable disease location per RECIST version 1.1.
- Have a tumor that expresses SSR confirmed by SSR imaging.
- Have an ECOG performance status of 0, 1, or 2.
- Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.
- Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.
- Use of anticancer agents within specified intervals prior to the first dose of study drug.
- Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.
- Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
- Participants with carcinoid syndrome.
- Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.
- Have prior treatment with MMAE.
- Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.
What is the full name of this Clinical Trial?
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
- Disease Type/ConditionSST2-Expressing Solid Tumors
- Principal InvestigatorJohn Smith
- Co-InvestigatorsAdam Smith, Amy Johnson
- Age GroupAdult, Older Adult
- PhaseII
- IRB NumberSTUDY07129252
- ClinicalTrials.gov IDNCT07129252
- Key Eligibilityclinicaltrials.gov
- How do I learn more about this study?Clinical Trial Recruitment
CancerTrialInformation@hoag.org
Cancer Institute
More Cancer Trials
(Elacestrant Versus Standard Endocrine Therapy in Early Breast Cancer With High Risk of Recurrence) Elacestrant Versus Standard Endocrine Therapy in Early Breast Cancer With High Risk of Recurrence
(Lung) Lung
(IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases) IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases